Neuroradiology Grants

Request for Proposals: Novel Approaches to Drug Discovery for Alzheimer’s Disease

ADDF funds drug discovery research programs from domestic and international investigators in academia and biotechnology companies. In addition, ADDF initiates, sponsors, and co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation, bringing together physicians, scientists, and policy makers worldwide.

As a biomedical venture philanthropy, ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development. We fund high risk, early stage drug discovery and development projects and catalyze scientists to enter the drug discovery field. We have adapted the operating model and principles of venture capital investing to our philanthropic mission in biomedical research. We help to create new biotechnology companies, and to fund early stage biotechnology companies, with programs dedicated to Alzheimer’s disease drug discovery. We seek a return on investment for all of our grants based on the achievement of scientific milestones. When these milestones are met, funds return to the Foundation to increase our ability to support more research.

ADDF FUNDING PROGRAMS
• ADDF Academic Drug Discovery and Development Program seeks to create and support innovative translational programs for Alzheimer’s disease, related dementias and cognitive aging in academic medical centers and universities. Biomarker development studies and innovative proof of concept pilot clinical trials of new approaches to treatment, prevention and early detection are also supported.

• ADDF Biotechnology Development Program supports qualified scientific projects in existing, private, early-stage biotechnology companies. ADDF will provide support for qualified projects in more advanced companies if a clear need for non-profit funding to support the project can be demonstrated and justified.

• ADDF Biotechnology Founders Technology Transfer Program supports academic programs that are eligible for technology transfer and the start-up of new biotechnology companies. Up to 35% of funds from these awards may be employed for expenses related to company formation, such as administrative, legal, patent and third-party vendor costs.

RESEARCH FUNDING PRIORITIES
• Treatment of Alzheimer’s disease and cognitive aging: ADDF supports drug discovery and drug development efforts towards novel treatments for Alzheimer’s disease and related dementias, and cognitive decline associated with aging. These may include disease modifying agents for preventing or delaying progression as well as cognitive enhancers. ADDF provides funding for target validation and proof-of-concept studies, high throughput screening of chemical libraries, lead discovery and optimization, rational medicinal chemistry, and pre-clinical drug development. ADDF also supports small proof-of principle clinical research studies.

• Early detection and prevention: ADDF supports the development of biomarkers, such as advanced brain imaging technologies, CSF and blood tests for the early detection of mild cognitive impairment, Alzheimer’s disease and related dementias. ADDF also supports clinical research projects to improve early detection of cognitive impairment through population-based approaches that can impact large numbers of individuals at risk.

GENERAL SUBMISSION GUIDELINES
Grant applications are usually solicited by private invitation. Unsolicited proposals are also accepted, but inquiries with ADDF staff are encouraged to determine the Foundation’s interest prior to application. ADDF provides support for 1 year of research with potential for future follow-on funding. We seek successful long-term partnerships with investigators and research organizations.

APPLICATION PROCEDURE
Full application guidelines and further information can be found on our website (www.alzdiscovery.org). All applicants are required to complete an electronic "Letter of Intent" (LOI) available on our website. After review of the LOI, we may invite a full application via email with a link to the electronic application form. ADDF will attempt to make a determination of interest within 90 days of receipt of the application.

ADDF accepts grant applications for the “General Request for Proposals” research award programs throughout the year (2010 deadlines for full proposals are January 7, April 1, July 1, and October 1).

If you would like to contact the Foundation, please call (212) 935-2402, or contact us by regular mail at the following address:

Alzheimer’s Drug Discovery Foundation
1414 Avenue of the Americas, Suite 1502
New York, NY 10019

Request for Proposals: Novel Approaches to Drug Discovery for Alzheimer’s Disease

ADDF funds drug discovery research programs from domestic and international investigators in academia and biotechnology companies. In addition, ADDF initiates, sponsors, and co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation, bringing together physicians, scientists, and policy makers worldwide.

As a biomedical venture philanthropy, ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development. We fund high risk, early stage drug discovery and development projects and catalyze scientists to enter the drug discovery field. We have adapted the operating model and principles of venture capital investing to our philanthropic mission in biomedical research. We help to create new biotechnology companies, and to fund early stage biotechnology companies, with programs dedicated to Alzheimer’s disease drug discovery. We seek a return on investment for all of our grants based on the achievement of scientific milestones. When these milestones are met, funds return to the Foundation to increase our ability to support more research.

ADDF FUNDING PROGRAMS
• ADDF Academic Drug Discovery and Development Program seeks to create and support innovative translational programs for Alzheimer’s disease, related dementias and cognitive aging in academic medical centers and universities. Biomarker development studies and innovative proof of concept pilot clinical trials of new approaches to treatment, prevention and early detection are also supported.

• ADDF Biotechnology Development Program supports qualified scientific projects in existing, private, early-stage biotechnology companies. ADDF will provide support for qualified projects in more advanced companies if a clear need for non-profit funding to support the project can be demonstrated and justified.

• ADDF Biotechnology Founders Technology Transfer Program supports academic programs that are eligible for technology transfer and the start-up of new biotechnology companies. Up to 35% of funds from these awards may be employed for expenses related to company formation, such as administrative, legal, patent and third-party vendor costs.

RESEARCH FUNDING PRIORITIES
• Treatment of Alzheimer’s disease and cognitive aging: ADDF supports drug discovery and drug development efforts towards novel treatments for Alzheimer’s disease and related dementias, and cognitive decline associated with aging. These may include disease modifying agents for preventing or delaying progression as well as cognitive enhancers. ADDF provides funding for target validation and proof-of-concept studies, high throughput screening of chemical libraries, lead discovery and optimization, rational medicinal chemistry, and pre-clinical drug development. ADDF also supports small proof-of principle clinical research studies.

• Early detection and prevention: ADDF supports the development of biomarkers, such as advanced brain imaging technologies, CSF and blood tests for the early detection of mild cognitive impairment, Alzheimer’s disease and related dementias. ADDF also supports clinical research projects to improve early detection of cognitive impairment through population-based approaches that can impact large numbers of individuals at risk.

GENERAL SUBMISSION GUIDELINES
Grant applications are usually solicited by private invitation. Unsolicited proposals are also accepted, but inquiries with ADDF staff are encouraged to determine the Foundation’s interest prior to application. ADDF provides support for 1 year of research with potential for future follow-on funding. We seek successful long-term partnerships with investigators and research organizations.

APPLICATION PROCEDURE
Full application guidelines and further information can be found on our website (www.alzdiscovery.org). All applicants are required to complete an electronic "Letter of Intent" (LOI) available on our website. After review of the LOI, we may invite a full application via email with a link to the electronic application form. ADDF will attempt to make a determination of interest within 90 days of receipt of the application.

ADDF accepts grant applications for the “General Request for Proposals” research award programs throughout the year (2010 deadlines for full proposals are January 7, April 1, July 1, and October 1).

If you would like to contact the Foundation, please call (212) 935-2402, or contact us by regular mail at the following address:

Alzheimer’s Drug Discovery Foundation
1414 Avenue of the Americas, Suite 1502
New York, NY 10019

Request for Applications for Projects With the Potential to Advance Basic Scientific and Translational Brain Aneurysm Research

The Brain Aneurysm Foundation invites applications for basic scientific research directed at early detection, improved treatment modalities, and technological advances that will ultimately improve outcomes for patients with brain aneurysms. Any project with the potential to advance basic scientific and translational brain aneurysm research will be considered. Clinical projects will not be funded.

The application due date is April 30, 2010.

When doing the budget portion of the application, please budget for the highest possible amount to be awarded, $40,000, even though you may receive a lesser amount.

Please contact Christine Buckley at 781 826 5556 or christine@bafound.org with any questions or concerns.

Brain Aneurysm Foundation
269 Hanover Street, Building 3
Hanover, MA 02339

Phone: 781-826-5556
or toll free 888-272-4602

Email: office@bafound.org

Michael J. Fox Foundation for Parkinson’s Research Request for Applications for Edmond J. Safra Core Programs for PD Research

Program Goal
With the current Request for Applications (RFA), The Michael J. Fox Foundation for Parkinson’s Research
(MJFF) seeks investigators to join the effort to develop new treatments and ultimately a cure for Parkinson’s
disease (PD). The Edmond J. Safra Core Programs for PD Research, part of our annual Pipeline Programs, is a
series of three funding opportunities that seek investigator-initiated proposals focused on the following critical
points along the translational pathway to new PD therapies:

· Testing Novel Hypotheses: Funding from our Rapid Response Innovation Awards program quickly
supports high-risk, high-reward projects with little to no existing preliminary data, but potential to
significantly impact our understanding or treatment of PD.
· Validating Novel Targets: Funding from our Target Validation program supports work demonstrating
whether modulation of a novel biological target has impact in a PD-relevant animal model – an essential
early step to the development of potential targeted therapies.
· Clinical Testing of Novel Therapies: Funding from our Clinical Intervention Awards program supports
clinical testing of promising PD therapies that may significantly and fundamentally improve treatment for
people with PD.

The Pipeline Programs, including The Edmond J. Safra Core Programs for PD Research, reflect our portfolio
approach to supporting work across multiple stages of development. Applicants are encouraged to carefully
consider the specific goals of each funding program to match the state of development for their project. Each
program requires submission of a custom ‘pre-proposal’ form summarizing the novel hypothesis, new target or
clinical trial being proposed. Applicants should not submit the same idea into multiple programs; rather, choose
the stage that is right for you. MJFF staff may choose at its discretion to move a proposal into the program that it
feels is most appropriate to the apparent stage of work.

Companies interested in support for early hypothesis testing, target validation or clinical efforts are welcome to
apply to the above programs. However, companies seeking support for preclinical therapeutic development
should also consider the separately launched, industry-only Therapeutics Development Initiative. Please see the
MJFF website for more information (www.michaeljfox.org).

Pre-proposals Due

Spring: December 15, 2009 6:00pm US ET
Fall: June 1, 2010 6:00pm US ET

For additional information about this initiative, contact the Foundation at research@michaeljfox.org.

If you would like to contact the Foundation, please send an email, call toll-free at 1-800-708-7644, or contact us by regular mail at the following address:

The Michael J. Fox Foundation for Parkinson's Research
Church Street Station
P.O. Box 780
New York, NY 10008-0780